Branch Retinal Vein Occlusion
In Case You Missed…Advancing Outcomes in Retinal Disease
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
Focal/grid laser treatment does not reduce ranibizumab injection frequency for macular edema
Data from the ZIPANGU study showed the use of focal/grid short-pulse laser therapy in patients receiving ranibizumab injections for the treatment of macular edema secondary to branch retinal vein occlusion did not reduce the number of necessary injections compared with patients undergoing ranibizumab monotherapy, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.